Alexion Pharmaceuticals | HealthCare Africa Magazine

AstraZeneca pumps US$ 200 million to acquire rights into Ionis’ rare disease drug

10 December 202110 December 2021

UNITED KINGDOM – AstraZeneca has announced that it would pay Ionis Pharmaceuticals, the market leader in RNA-targeted therapies, US$200 million for the rights to its investigational medicine, eplontersen. Eplontersen is…

AstraZeneca completes its US$39B buyout deal of Alexion as it sets to expand its portfolio into rare diseases

23 July 202123 July 2021

UK – AstraZeneca has completed its buyout process of Alexion pharmaceuticals in a move that will see the British pharma giant venture extensively into immunology medicines and rare disease therapy.…

AstraZeneca’s acquisition of Alexion near completion following clearance from European Commission

6 July 20216 July 2021

UK – AstraZeneca, a British-Swedish multinational pharmaceutical and biotechnology company, is finally on course to secure Alexion, a pharma company that specializes in rare disease, following a go-ahead approval from…